Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)

NCT Number	NCT07245771
Lead Sponsor	Ikaria Bioscience Pty Ltd Collaborators: Shanghai Rona Therapeutics Co., Ltd.
Conditions	Obesity & Overweight
Enrollment	104 participants
Start Date	2025-11-04
Primary Completion	2027-02-15 (estimated)
Study Completion	2027-08-15 (estimated)
Updated on ClinicalTrials.gov	2025-11-24